Start Your Search
P3.04 - Immunooncology (Not CME Accredited Session) (ID 970)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
P3.04-05 - Programmed Death-Ligand 1 of Cytology Specimens as a Promising Method for Maker Evaluation in Patients of Non-Small Cell Lung Cancer (ID 13123)
12:00 - 13:30 | Presenting Author(s): Zhengwei Dong
Measuring programmed death-ligand 1 (PD-L1) expression has been commonly used to classify the promising patients for immunotherapy. PD-L1 heterogeneous expression has been elucidated within the tumor. Therefore, we questioned whether small tissue samples, such as cytology samples, sufficiently represented PD-L1 expression in non-small cell lung cancer(NSCLC).
Paired cytological cell block and surgical resection before systemic therapy was assessed. PD-L1 expression was quantified by using both 28-8 and SP142 assays. Feasibility of PD-L1 expression in cell blocks was compared with that in matched surgical resection with various cutoffs.4c3880bb027f159e801041b1021e88e8 Result
A total of 112 pairs of specimens were collected at the time of initial diagnosis, including 79(63.2%) adenocarcinomas and 28(25.0%) squamous cell carcinomas. PD-L1 expression showed fair to substantial concordance between cytology specimens and surgical resection for both antibodies’ staining ( 8eea62084ca7e541d918e823422bd82e Conclusion
PD-L1 expression of cytology specimens with high tumor cells showed concordance with surgical resection. These findings suggested that cytology specimens might be adequate representative for PD-L1 expression of patients with NSCLC.6f8b794f3246b0c1e1780bb4d4d5dc53
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.